May 11, 2025 - 01:02

Mother’s Day is a bustling time for florists, and this year is no exception for businesses like Hydrangea Bloom in Iowa. However, florists are facing significant challenges due to rising prices linked to tariffs imposed during the Trump administration. Allison Krivachek, the owner of Hydrangea Bloom, has found herself in a difficult position as the costs of imported flowers continue to climb.
As a result, Krivachek has had to raise her prices, which has led to a noticeable decline in customer orders. Many customers are feeling the pinch of higher prices, and some are opting for smaller arrangements or even skipping flowers altogether. This situation has created a ripple effect in the local floral industry, where many rely on Mother’s Day sales to boost their annual revenue.
Florists are now grappling with the dual challenge of maintaining quality while managing costs. As Mother’s Day approaches, the uncertainty surrounding pricing and supply chain issues looms large for those in the floral business.
November 8, 2025 - 03:20
The Impact of Research in Business EducationIn academia, the importance of research extends beyond mere publications; it serves as a powerful tool to influence and shape the business landscape. Recent evaluations have highlighted the most...
November 7, 2025 - 00:24
Regenstrief Institute Joins Forces with Indiana University and Eli Lilly in Groundbreaking Health InitiativeRegenstrief Institute has been recognized as a key collaborator in the Indiana Musculoskeletal Health Partnership for the Advancement of Care & Treatment (IMPACT). This innovative consortium,...
November 6, 2025 - 04:29
Google Explores Expanded Investment in AnthropicGoogle is reportedly in preliminary talks to increase its investment in Anthropic, a leading artificial intelligence research company. This potential move comes on the heels of a significant...
November 5, 2025 - 19:07
Genelux Corporation Releases Q3 2025 Financial Results and Business UpdatesGenelux Corporation has shared its financial results for the third quarter of 2025, highlighting significant advancements in its lung cancer programs. The company anticipates interim data updates...